Please login to the form below

Not currently logged in
Email:
Password:

GW Pharmaceuticals

This page shows the latest GW Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

GW Pharma’s Epidyolex also on the recommended list. Bayer’s Vitrakvi has become the first drug in Europe recommended to treat cancer based on a molecular signature, rather than where ... The CHMP has also granted a positive opinion for GW Pharma’s

Latest news

  • GW Pharma's cannabis-based medicine to be tested in dementia GW Pharma's cannabis-based medicine to be tested in dementia

    Trial will be funded by Alzheimer’s Research UK. Alzheimer’s Research UK is to sponsor a clinical trial of GW Pharmaceuticals’ Sativex to treat agitation and aggression in people with

  • Orchard surpasses IPO expectations, raising $200m Orchard surpasses IPO expectations, raising $200m

    flow. Orchard now joins a cluster of European biotechs, including the likes of GW Pharmaceuticals and Genmab, that are worth 1bn or more.

  • The year of the blockbuster The year of the blockbuster

    Emanating from the pipelines of global pharma giants like Novartis, Johnson &Johnson and Pfizer, as well companies such as Denmark’s Novo Nordisk and Indivior and GW Pharmaceuticals, both of the ... Epidiolex from GW Pharmaceuticals:With a PDUFA date

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Phase III: opioid agonists. GW Pharmaceuticals has developed a buccal spray known as nabiximols or Sativex, which comprises delta-9-tetrahydrocannabinol (27mg/mL) and cannabidiol (25mg/mL), as an analgesic agent ... WEX Pharmaceuticals is conducting a

  • Almirall launches Sativex in Italy Almirall launches Sativex in Italy

    The drug, developed by GW Pharmaceuticals, was approved by Italian authorities in May and comes to the market with a reimbursed priced that GW said was “consistent with the reimbursed … price ... Sativex has been given a rolling launch in Europe,

More from news
Approximately 2 fully matching, plus 43 partially matching documents found.

Latest appointments

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    Appoints Dr Volker Knappertz and Professor Ben Whalley. GW Pharmaceuticals has appointed Dr Volker Knappertz (pictured right) as its chief medical officer (CMO), a role that will see him based at ... I look forward to contributing to GW’s drug

  • GW Pharmaceuticals promotes Adam George to MD GW Pharmaceuticals promotes Adam George to MD

    And Scott Giacobello joins as chief financial officer. UK biopharma company GW Pharmaceuticals has promoted chief financial officer Adam George to UK managing director. ... Gover said: “These important leadership appointments reflect GW’s continuing

  • GW hires Pfizer’s Kenneth Sommerville GW hires Pfizer’s Kenneth Sommerville

    Appointed VP clinical research at company specialising in cannabinoids. Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma. ... Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics